Eradication

Current Opinion in Gastroenterology

Volumn 12, Issue SUPPL. 1, 1996, Pages 37-40

  Pajares García, José ^a   Bazzoli, Franco ^b  

^a Club of Madrid   (Spain)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BISMUTH; CLARITHROMYCIN; FAMOTIDINE; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; SPIRAMYCIN; TETRACYCLINE; TINIDAZOLE;

BACTERIAL INFECTION; DRUG COST; DRUG EFFICACY; HELICOBACTER PYLORI; HUMAN; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PEPTIC ULCER; SHORT SURVEY; SIDE EFFECT; TREATMENT PLANNING;

EID: 0029999956     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199601001-00009     Document Type: Short Survey

References (32)

1. Bell GD: Conference report: duodenal ulcer trials reported at the European Helicobacler pylori study group workshop, Edinburgh, 1995. Aliment Pharmacol Ther 1996, 10:49-54.
2. Berstad A, Berstad K, Wilhelmsen I, Hatlebakk JG, Nesje LB, Hausken T: Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up. Aliment Pharmacol Ther 1995, 9:197-200. The macrolide, spiramycin, may be an alternative antibiotic for eradication.
3. Sung JJY, Chung S, Ling TKW, Yee Yung M, Leung VKS, No EKW, Li MKK, Cheng AFB, Li AKC: Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995, 332:139-143. Impressively good results in healing gastric ulcers were obtained with antibiotic treatment without acid suppression.
4. Sung YJ, Leung V, Chung S, Ling TK, Suen R, Cheng AF, Li AK: Triple therapy with sucralfate, tetracycline and metronidazole for Helicobacter pylori-associated duodenal ulcers. Am J Gastroenterol 1995, 90:1424-1427. Sucralfate may be a component of the eradication regimen but bismuth combinations give better results.
5. Seppala K, Pikkarainen P, Sipponen P, Krvilaakson E, Gormen MH and the Finnish Gastric Ulcer Study Group: Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Gut 1995, 36:834-837. Healing of gastric ulcers is rapid and recurrence is infrequent after successful H. pylori eradication.
6. De Boer WA, Driessen WMM, Arjan RJ, Tytgat GNJ: Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of randomized prospective single-centre study. Eur J Gastroenterol Hepatol 1995, 7:1189-1194. A randomized study showing that quadruple therapy is well tolerated. This therapy is indicated as a second-line treatment for metronidazole-resistant patients.
7. Borody TJ, Andrews P, Fracchia G, Brandi S, Shortis NP, Bae H: Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995, 37:477-481. The addition of omeprazole to a bismuth triple therapy enhances enormously the eradication rate.
8. Jaup BH, Norrby A: Low dose short term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcer. Am J Gastroenterol 1995, 90:943-945.
9. Yousfy MM, El-Zimaity HMT, AOI-Assi MT, Cole RA, Genta RM, Graham DY: Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995, 9:209-212. This combination has proved to be effective for the eradication of metronidazole-resistant strains.
10. Bell GD, Powell KU, Burridge SM, Bowden AF, Atoyebi W, Bolton GH, Jones PH Browns C: Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995, 9:41-46. In a large number of patients, the results of the triple therapy of omeprazole, amoxycillin and metronidazole, administered at different durations, confirmed the excellent results of the 1-week regimen but with fewer side effects.
11. Moayyedi P, Sahay P, Tompkins DS, Axon ATR: Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol 1995, 7: 835-840.
12. Labenz J, Stolte M, Rurhl G, Becker T, Tillenburg B, Sollbohmer M: One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995, 7:9-11.
13. Goddard A, Logan R: One-week low-dose triple therapy: new standards for Helicobacter pylori treatment. Eur J Gastroenterol Hepatol 1995, 7:1-3. This review provides data indicating that 1 -week duration of the omeprazole triple therapy achieves a very high and constant rate of eradication.
14. Yousfy MM, El Zimairy HMT, Cole RA, Genta RM, Graham DY: Metronidazole, ranitidine and clarithromycin in combination treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Aliment Pharmacol Ther 1996, 10:119-122.
15. Adamek RJ, Opferkuch W, Wegener M: Modified short-term triple therapy - ranitidine, clarithromycin and metronidazole - for cure of Helicobacter pylori infection. Am J Gastroenterol 1995, 90:168-169.
16. Laine L, Stein C, Neil G: Limited efficacy of omeprazole-based dual and triple therapy for Helicobacter pylori: a randomized trial employing 'optimal' dosing. Am J Gastroenterol 1995, 90:1407-1410.
17. Bertoni G, Sassatelli R, Nigrisoli E, Tansini P, Bianchi G, Della casa G, Bagni A, Bedogni G: Triple therapy with azithromycin, omeprazole and amoxycillin is highly effective in the eradication of Helicobacter pylori: a controlled trial versus omeprazole plus amoxicillin. Am J Gastroenterol 1996, 91:258-263. The randomized comparative study showing that the macrolide, azithromycin, is also very effective in triple therapy to eradicate H. pylori.
18. Di Mario F, Dal Bó N, Grassi SA, Rugge M, Cassaro M, Donisi PM, Vianello F, Kusstatscher S, Salandin S, Grasso GA et al.: Azithromycin for the cure of Helicobacter pylori infection. Am J Gastroenterol 1996, 91:264-267.
19. Logan RPH, Walker MM, Misiewicz JJ, Gummet PA, Karim QN, Baron JH: Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995, 36:12-16. The potent inhibition by omeprazole of gastric secretion produces changes in the distribution of H. pylori in the gastric mucosa. This fact should be considered in diagnosis.
20. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen H, Liedman B, Lamers C, Jansen JBMJ, Dalenbäck J, Snel P et al.: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fondoplication. N Engl J Med 1996, 334: 1018-1022. Patients with reflux oesophagitis and H. pylori infection, who are treated with omeprazole, are at increased risk of atrophic gastritis and should, therefore, be considered for an eradication treatment.
21. Kimura K, Kenichi I, Kouji S, Ido K, Saifuku K, Tanigusci Y, Kihira K, Satoh K, Takimoto T, Yoshida Y: A 1-h topical therapy for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1995, 90:60-63. This original method is very effective, although very uncomfortable for the patients. It is unlikely to have a practical application.
22. Bayerdörffer E, Miehlke S, Gerd A, Mannes G, Sommer A, Hochter W, Weingart J, Heldwein W, Klann H, Simon T et al.: Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995, 108:1412-1417. An increase in the eradication rate with high doses of omeprazole was demonstrated. Most authors, however, obtain good results with the standard 40 mg daily dose.
23. Sobhani I, Chastang C, De Korwin JD, Lamouliate H, Mégraud F, Guerre J, Elouaer-Blanc L: Antibiotic versus maintenance therapy in the prevention of duodenal ulcer recurrence. Results of a multicentric double-blind randomized trial. Gastroenterol Clin Biol 1995,19:252-258. A small-scale study demonstrating that the eradication of H. pylori is as effective as maintenance therapy and that it costs less.
24. Xia HX, Gilvarry J, Beattie S, Hamilton H, Keane CT, Eamosn CPI, Sweeney C, O'Morain. C: Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens. Am J Gastroenterol 1995, 90:1221-1228. Recrudescence and reinfection are critically analysed after different eradication regimens.
25. Lazzaroni M, Maconi G, Bargiggia S, Minguzzi M, Bianchi Porro G: Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. Eur J Gastroenterol Hepatol 1995, 7:117-119.
26. Louw JA, Lucke W, Jaskwicz K, Lastovica AJ, Winter TA, Marks IN: Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence. Gut, 36:544-547. Consistently low rates of reinfection were found in African communities with a high prevalence of H. pylori infection.
27. Miehlke S, Bayerdörffer E, Lehn N, Mannes GA, Höchter W, Weingart J, Sommers A, Heldwein W, Müller-Lissner S, Bästlein E, et al: Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995, 7:975-978. A long follow-up European multicentre study in duodenal ulcer patients after eradication of H. pylori.
28. Martin JG, Diament RH, Dixon MF, Axon ATR, Johnston D: Helicobacter pylori and recurrent ulceration after highly selective vagotomy. Eur J Gastroenterol Hepatol 1995, 7:207-209.
29. Reilly TG, Ayres RCS, Poxon V, Walt RP: Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 1995, 9:483-490.
30. Graham DY: A reliable cure for Helicobacter pylori infection? Gut 1995, 37:154-156. On the basis of his personal experience, the author comments on a practical way of evaluating anti-H. pylori trials and the most rational approach to making a decision on the choice of drugs and on the duration of the eradication regimen.
31. Moshkowitz M, Konikoff FM, Peled Y, Santo M, Bujanover Y, Tiomny E: High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995, 36:845-847. The pre-treatment urease activity assessed by the urea breath test may be an important factor in predicting H. pylori eradication. For potential clinical applications these data warrant further confirmation.
32. Atherton JC, Cockayne A, Balsitis M, Kirk GE, Spiller RC: Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxycillin and cimetidine. Gut 1995, 36:670-674. This study demonstrates that H. pylori may escape from the antrum to the gastric body and fundus after treatment with a non-potent antisecretory drug and an antibiotic.